Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD

Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Dominick J. Angiolillo(University of Florida), Francesco Franchi(Florida College), Tiffany Ossi(University of Florida), Fabiana Rollini(Florida College), Mattía Galli(Maria Cecilia Hospital), Latonya Been(University of Oklahoma Health Sciences Center), Awss Shalhoub(University of Florida), Siva Suryadevara(University of Florida), Taimour Langaee(University of Florida), Larisa H. Cavallari(University of Florida), Ghussan Ghanem(University of Florida), Xuan Zhou(University of Florida), Andrés M. Pineda(University of Florida), Daniel Soffer(University of Florida), Martin M. Zenni(University of Florida), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Andrea Rivas(University of Florida), Madeline Mahowald(University of Florida)
JACC Basic to Translational Science
March 25, 2024
10.1016/j.jacbts.2024.03.003
Cited by 3

Related Papers

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility
|Nature Genetics|2014|1.1k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651